Showing 3621-3630 of 6808 results for "".
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in
- Nielsen BioSciences, Maruho Co. Ltd. Enter License Agreement for the Treatment of Common Wartshttps://practicaldermatology.com/news/nielsen-biosciences-maruho-co-ltd-enter-license-agreement-for-the-treatment-of-common-warts/2461719/Nielsen BioSciences, Inc.</
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an
- Stony Brook University Hospital and The Mollie Biggane Melanoma Foundation Promote Skin Cancer Prevention Through New Inpatient Initiativehttps://practicaldermatology.com/news/stony-brook-university-hospital-and-the-mollie-biggane-melanoma-foundation-promote-skin-cancer-prevention-through-new-inpatient-initiative/2461709/Stony Brook University Hospital (SBUH) and the Mollie Biggane Melanoma Foundation announce a collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program, according to a news release. Historicall
- DermTech Appoints Bret Christensen as New President and CEOhttps://practicaldermatology.com/news/dermtech-appoints-bret-christensen-as-new-president-and-ceo/2461707/DermTech announced the appointment of Bret Christensen as president, chief executive officer, and a member of the board of directors. Mr. Christensen, who was previously chief commercial officer of Insulet, succeeds Dr. John Dobak, who stepped down as president, CEO and a dir
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- Study: DecisionDx-Melanoma May Lead to Earlier Melanoma Detection, Decreased Metastatic Tumor Burdenhttps://practicaldermatology.com/news/study-decisiondx-melanoma-may-lead-to-earlier-melanoma-detection-decreased-metastatic-tumor-burden/2461698/The use of Castle Biosciences, Inc. DecisionDx-Melanoma test results to guide radiological surveillance may lead to improved patient outcomes, according to a new study in Archives of Dermatological Research. The new study, conducted at three National Cancer Institute-desig
- U.S. FDA Grants Breakthrough Therapy Designation to Spevigo for the prevention of GPP Flareshttps://practicaldermatology.com/news/us-fda-grants-breakthrough-therapy-designation-to-spevigo-for-the-prevention-of-gpp-flares-1/2461694/The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to Spevigo for the prevention of generalized pustular psoriasis (GPP) flares, Boehringer Ingelheim reports. This designation follows the Center for Drug Evaluation (CDE) of China National Medic